<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-165878</identifier>
<setSpec>1137-6627</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Olmesartan-associated enteropathy: attention to an emerging iatrogenic phenomenon</dc:title>
<dc:description xml:lang="en">Olmesartan is an angiotensin II type 1 receptor blocker commonly used in the treatment of hypertension. Several cases of sprue-like enteropathy associated with the use of this drug have been described which, even with important signs and limitations for the patient, present a full recovery after discontinuing the use of olmesartan. The case of a 64 year-old patient is presented, diagnosed with hypertension, under treatment with olmesartan- amlodipine, with chronic diarrhoea and villous atrophy on intestinal biopsies without diagnostic criteria for celiac disease and with complete remission after suspending discontinuing the use of olmesartan. Based on the clinical features presented by the case reported, the clinical and anatomopathological findings are described as well as the evolution of drug-induced enteropathy (AU)</dc:description>
<dc:creator>González, P</dc:creator>
<dc:creator>Aguiar, B</dc:creator>
<dc:creator>Modesto, J</dc:creator>
<dc:creator>Terry, O</dc:creator>
<dc:creator>Leturia, I</dc:creator>
<dc:creator>Elejalde, I</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">El olmesartán es un antagonista del receptor tipo 1 de la angiotensina II utilizado habitualmente en el tratamiento de pacientes con hipertensión arterial. Recientemente se han descrito varios casos de enteropatía sprue-like asociados al uso de este fármaco, con afectación clínica importante y total remisión tras la retirada del mismo. Se presenta el caso de un varón de 64 años, con antecedentes de hipertensión arterial en tratamiento con olmesartan-amlodipino con clínica de diarrea y pérdida de peso severas, atrofia vellositaria en biopsia duodenal sin criterios de enfermedad celiaca y remisión completa del cuadro tras la supresión del olmesartán. Basado en los hallazgos del caso clínico presentado, se revisan las manifestaciones clínicas e histopatológicas así como el curso evolutivo de una posible causa de enteropatía farmacológica recientemente descrita (AU)</dc:description>
<dc:source>An Sist Sanit Navar;40(2): 291-294, mayo-ago. 2017. ilus</dc:source>
<dc:identifier>ibc-165878</dc:identifier>
<dc:title xml:lang="es">Enteropatía asociada a olmesartán: atención a un fenómeno iatrogénico emergente</dc:title>
<dc:subject>^d29396^s22045</dc:subject>
<dc:subject>^d21012</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d22921^s22074</dc:subject>
<dc:subject>^d3965</dc:subject>
<dc:subject>^d55915^s22020</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d22334^s22020</dc:subject>
<dc:subject>^d1290^s22036</dc:subject>
<dc:subject>^d8459^s22012</dc:subject>
<dc:subject>^d3994^s22012</dc:subject>
<dc:subject>^d8459^s22036</dc:subject>
<dc:subject>^d9062</dc:subject>
<dc:subject>^d3994^s22016</dc:subject>
<dc:type>article</dc:type>
<dc:date>201708</dc:date>
</metadata>
</record>
</ibecs-document>
